Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has announced the outcome of its Board Meeting held on August 26, 2026, where it approved several key decisions, including the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers to determine materiality of events or information. The company also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and proposed the incorporation of a Subsidiary Company in Canada to support its business and strategic objectives in the Canadian and other international markets.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026, where the Board approved the appointment of Company Secretary and Compliance Officer, Non-Executive Additional Director, authorized officers for determining materiality of events, and approved the adoption of Employee Stock Option Scheme 2026 and proposed incorporation of Wholly Owned Subsidiary in Mexico and Subsidiary Company in Canada.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding the outcome of its Board Meeting held on August 26, 2026, where it approved the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers to determine materiality of events or information and make disclosures to stock exchanges. The Board also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private Limited, Subsidiary of the Company from ICICI Bank Limited.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange about the schedule of meet with analysts/institutional investors, to be held on August 25, 2026, at Antique Stock Broking Group in Mumbai.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has announced the outcome of its postal ballot, where shareholders have passed the ordinary and special resolutions with the requisite majority.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding Transcript of Earnings Conference Call held on Monday, July 27, 2026 for Q1FY27.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has published unaudited financial results for the quarter ended June 30, 2026, as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has made the audio recording of its earnings conference call for the quarter ended June 30, 2026, available on its website.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 for the quarter ended June 30, 2026, stating that there has been no deviation(s) or variation(s) in the utilization of funds raised through preferential issue of convertible equity warrants.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 for the quarter ended June 30, 2026. The company has confirmed that there has been no deviation(s) or variation(s) in the utilization of proceeds of IPO for the mentioned period. However, there is a delay in the going concern principle for investment in one of our subsidiaries, Havix, to fund deployment of capital of funds expenditure under requirements for setting up a manufacturing company facility for the production of sterile injections in our Atlanta facility.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations, detailing the utilization of IPO proceeds. The report indicates that there is an ongoing delay in implementation of one of the objects of the issue, which was scheduled to be completed by a Chartered Accountant.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange about Investor Presentation for Q1FY27, with robust performance and revenue growth of 36% Y-o-Y, and EBIDTA growth of 87% with margin expansion of ~800 bps on a Y-o-Y basis.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue growing by 36% year-over-year, EBITDA increasing by 87%, and PAT growing by 56%. The company has also expanded its product portfolio, with a strong focus on regulated and emerging markets.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding the appointment of Ms. Anjali Shah as Assistant Vice President-Finance as Senior Management Personnel (SMP) of the company with effect from July 27, 2026.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on July 27, 2026. The meeting commenced at 01:45 P.M. (IST) and concluded at 02:55 P.M. (IST). The Board approved the appointment and categorization of Ms. Anjali Shah, Assistant Vice President-Finance as Senior Management Personnel of the Company with effect from July 27, 2026. The unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, together with the Limited Review Report thereon, were also approved.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has announced its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, along with the limited review report of its statutory auditors. The company has also announced the appointment of Ms. Anjali Shah as Senior Management Personnel with effect from July 27, 2026.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has scheduled an earnings conference call for Q1FY27 on July 27, 2026, following the announcement of unaudited consolidated and standalone financial results for the quarter ended June 30, 2026.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has submitted the Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2026, as per SEBI (Depositories and Participants) Regulations, 2018.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, confirming the acceptance or rejection of dematerialized securities and listing of securities on stock exchanges.